Thymidine Analogues

Each time a new assay is developed, it must be better than the established method and it is not disadvantageous. In other words, ultimately, it is necessary to provide more researchers with more power by providing more accurate results and allowing more information to be gathered. Measurement of neurogenesis by incorporation of thymidine analogs is an important tool in many neurological studies, but many limitations on the current "gold standard" make decisive importance on excellent assay development There.

Thymidine analog NRTI (AZT, especially d 4 T) is associated with fat loss. When d4T / AZT is replaced by TDF or ABC, fat atrophy is improved but its solution is very slow and often incomplete; therefore, it is desirable to identify fat atrophy early, or more preferably It is important to use NRTI that is not related to state. In the past, PI was thought to be the cause of fat hypertrophy. However, recent studies have shown that all ART classes are associated with increased fat. In addition, longitudinal studies comparing long-term antiretroviral therapy of HIV-negative patients and HIV-positive patients also showed similar levels and distribution of fat increases. A systematic review of the conversion of ART for RCT of fat accumulation did not show any benefit 63 These data suggest that fat increase is the result of HIV treatment rather than drug specific side effects There.

Since the first introduction of GnRH analogs in the early 1980's, they have been recognized as premature puberty therapies and in 1993 one of the famous GnRH analogs for such use Lupron Was approved by the FDA. However, there is still some doubt about the efficacy of GnRH analog treatment. A recent consensus statement by pediatric endocrinologists concluded that GnRH analogs are an effective way to improve the height of adolescent girls under 6 years of age and to recommend treatment for boys with premature puberty. High possibilities With respect to the negative psychological and social influences associated with precocious puberty, the authors find that the available data are unconvincing and require further study.

Premature puberty treatment is a bit contrary to intuition. In practice, physicians do not stop production of GnRH but rather provide a more constant level of synthetic GnRH (called GnRH analog or GnRH agonist) to patients. Excess GnRH "desensitizes" the pituitary gland resulting in a decrease in the secretion of gonadotropin (LH and FSH), which in turn leads to a decrease in sex hormone maturation and secretion in the gonads (ovary and testis) . The first publication describing the use of GnRH analogs for children's premature puberty was published in 1981.